New drug tested for Tough-to-Treat stomach and digestive cancers
NCT ID NCT05411133
Summary
This early-stage study tested a new drug called cabotamig in 33 adults with advanced gastrointestinal cancers that had stopped responding to standard treatments. The main goals were to check the drug's safety, see how the body processes it, and look for early signs it might help shrink tumors. Participants had cancers like colorectal, pancreatic, or stomach cancer that showed a specific marker called CDH17.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Southern Oncology Clinical Research Unit
Adelaide, Australia
-
St George Private Hospital
Sydney, Australia
Conditions
Explore the condition pages connected to this study.